These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 31174610)

  • 1. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide.
    Lee C; Jeong H; Bae Y; Shin K; Kang S; Kim H; Oh J; Bae H
    J Immunother Cancer; 2019 Jun; 7(1):147. PubMed ID: 31174610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Effect of Melittin-dKLA Targeting Tumor-Associated Macrophages in Melanoma.
    Han IH; Jeong C; Yang J; Park SH; Hwang DS; Bae H
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
    Kim S; Choi I; Han IH; Bae H
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
    Lee C; Kim S; Jeong C; Cho I; Jo J; Han IH; Bae H
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model.
    Lee C; Bae SS; Joo H; Bae H
    Oncotarget; 2017 Aug; 8(33):54951-54965. PubMed ID: 28903394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melittin derived peptide-drug conjugate, M-DM1, inhibits tumor progression and induces effector cell infiltration in melanoma by targeting M2 tumor-associated macrophages.
    Jeong C; Kim J; Han IH; Kim S; Choi I; Kim H; Jeong JH; Bae H
    Front Immunol; 2023; 14():1178776. PubMed ID: 37122692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
    Cieslewicz M; Tang J; Yu JL; Cao H; Zavaljevski M; Motoyama K; Lieber A; Raines EW; Pun SH
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15919-24. PubMed ID: 24046373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of MEL-dKLA by targeting M2 macrophages in pulmonary fibrosis.
    Choi I; Han IH; Cha N; Kim HY; Bae H
    Biomed Pharmacother; 2024 Sep; 178():117246. PubMed ID: 39096617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide.
    Lepland A; Asciutto EK; Malfanti A; Simón-Gracia L; Sidorenko V; Vicent MJ; Teesalu T; Scodeller P
    Mol Pharm; 2020 Jul; 17(7):2518-2531. PubMed ID: 32421341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
    Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
    J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    Li H; Huang N; Zhu W; Wu J; Yang X; Teng W; Tian J; Fang Z; Luo Y; Chen M; Li Y
    BMC Cancer; 2018 May; 18(1):579. PubMed ID: 29783929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.
    Tariq M; Zhang JQ; Liang GK; He QJ; Ding L; Yang B
    Acta Pharmacol Sin; 2017 Nov; 38(11):1501-1511. PubMed ID: 29022575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
    Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
    Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype.
    Dong H; Yang Y; Gao C; Sun H; Wang H; Hong C; Wang J; Gong F; Gao X
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective targeting of tumor associated macrophages in different tumor models.
    Kakoschky B; Pleli T; Schmithals C; Zeuzem S; Brüne B; Vogl TJ; Korf HW; Weigert A; Piiper A
    PLoS One; 2018; 13(2):e0193015. PubMed ID: 29447241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor-associated macrophages in the tumor microenvironment.
    Zhou K; Cheng T; Zhan J; Peng X; Zhang Y; Wen J; Chen X; Ying M
    Oncol Lett; 2020 Nov; 20(5):234. PubMed ID: 32968456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses.
    Wang YC; He F; Feng F; Liu XW; Dong GY; Qin HY; Hu XB; Zheng MH; Liang L; Feng L; Liang YM; Han H
    Cancer Res; 2010 Jun; 70(12):4840-9. PubMed ID: 20501839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.